Actelion reports earnings

Actelion Ltd. (SIX:ATLN) reported 4Q09 revenues of CHF470 million ($435.8 million), up 16% from CHF403.9 million in 4Q08. Fourth quarter sales of Tracleer bosentan for pulmonary arterial hypertension (PAH) were CHF393.3 million ($379.7 million), up 13% from CHF348.3 million in 4Q08. Actelion reported a 4Q09 diluted GAAP loss per share of CHF0.13, compared to diluted GAAP EPS of CHF0.64 in the prior year's quarter. ...